CAS 2079-89-2|3-aminopropionitrile fumarate
Introduction：Basic information about CAS 2079-89-2|3-aminopropionitrile fumarate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | 3-aminopropionitrile fumarate | ||
|---|---|---|---|
| CAS Number | 2079-89-2 | Molecular Weight | 186.165 |
| Density | / | Boiling Point | 355.5ºC at 760 mmHg |
| Molecular Formula | C7H10N2O4 | Melting Point | 177 °C (dec.)(lit.) |
| MSDS | ChineseUSA | Flash Point | 183ºC |
| Symbol | GHS08 | Signal Word | Danger |
Names
| Name | 3-aminopropionitrile fumarate |
|---|---|
| Synonym | More Synonyms |
3-aminopropionitrile fumarate BiologicalActivity
| Description | 3-Aminopropionitrile fumarate (2:1) is a lathyrogen which inhibits crosslinking of collagen. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>Others |
| Target | Collagen[1]. |
| In Vivo | Twenty days after the induction of tendinitis, intralesional treatment with 3-Aminopropionitrile fumarate (2:1) (BAPN-F) is performed and the contralateral limbs receive saline. A biopsy is obtained and gross and histopathological analysis is performed on the 150 th day of the experiment. The collagen fibrillar alignment pattern in the healing area is better in the 3-Aminopropionitrile fumarate (2:1) group submitted to controlled exercise than in the other group, as observed by sonographic and histopathologic examination. The present results indicate that 3-Aminopropionitrile fumarate (2:1) in combination with controlled loading improved scar remodeling and tendon wound collagen maturation[1]. |
| Animal Admin | Horses[1] Seven female and nine male horses are assigned at random to two groups (G1 and G2) submitted to different treatments after the induction of acute tendinitis. Each group consists of eight animals injected with type 1 collagenase, 1 mL, 2.5 mg/mL, in the middle metacarpal third into the superficial digital flexor tendons of both forelimbs. Twenty days after the injection of collagenase, one of the limbs (G1A/G2A) receives an injection of 3-Aminopropionitrile fumarate (2:1), 3 mL, 0.8 mg/mL, and the other limb (G1B) receives the same volume of buffered saline as control. Group one was left in box rest, and group two was submitted to controlled exercise during the experiment[1]. |
| References | [1]. A.L.G. Alves, et al. Effects of beta-aminopropionitrile fumarate and exercise on equine tendon healing: gross and histological aspects. Journal of Equine Veterinary Science, 2001, 21 (7) :335-340. |
Chemical & Physical Properties
| Boiling Point | 355.5ºC at 760 mmHg |
|---|---|
| Melting Point | 177 °C (dec.)(lit.) |
| Molecular Formula | C7H10N2O4 |
| Molecular Weight | 186.165 |
| Flash Point | 183ºC |
| Exact Mass | 186.064056 |
| PSA | 124.41000 |
| LogP | 0.27088 |
| Vapour Pressure | 5.19E-06mmHg at 25°C |
| InChIKey | NYMXYZMHOZAPHQ-SEPHDYHBSA-N |
| SMILES | N#CCCN.N#CCCN.O=C(O)C=CC(=O)O |
| Storage condition | -20°C |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 800 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 5,33,1972
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Administration onto the skin
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 23130 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- EXMPA6 Experimental and Molecular Pathology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1962- Volume(issue)/page/year: 39,154,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 5362 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- EXMPA6 Experimental and Molecular Pathology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1962- Volume(issue)/page/year: 39,154,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - hamster
- DOSE/DURATION :
- 5 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 14,43,1976 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1 gm/kg
- SEX/DURATION :
- female 15 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- REFERENCE :
- TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 24,43,1981
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 600 mg/kg
- SEX/DURATION :
- female 15 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- REFERENCE :
- DEBIAO Developmental Biology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 27,327,1972
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1 gm/kg
- SEX/DURATION :
- female 17 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- REFERENCE :
- TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 10,165,1974
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1200 mg/kg
- SEX/DURATION :
- female 15-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetal death
- REFERENCE :
- ARPAAQ Archives of Pathology. (Chicago, IL) V.5(3)-50(3), 1928-50; V.70-99, 1960-75. For publisher information, see APLMAS. Volume(issue)/page/year: 81,60,1966
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1200 mg/kg
- SEX/DURATION :
- female 13-18 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - homeostasis Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
- REFERENCE :
- ARPAAQ Archives of Pathology. (Chicago, IL) V.5(3)-50(3), 1928-50; V.70-99, 1960-75. For publisher information, see APLMAS. Volume(issue)/page/year: 81,60,1966
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 1800 mg/kg
- SEX/DURATION :
- female 14-16 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- REFERENCE :
- FCTXAV Food and Cosmetics Toxicology. (London, UK) V.1-19, 1963-81. For publisher information, see FCTOD7. Volume(issue)/page/year: 10,839,1972
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1800 mg/kg
- SEX/DURATION :
- female 13-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- REFERENCE :
- FCTXAV Food and Cosmetics Toxicology. (London, UK) V.1-19, 1963-81. For publisher information, see FCTOD7. Volume(issue)/page/year: 10,839,1972
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 2700 mg/kg
- SEX/DURATION :
- female 14-16 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- REFERENCE :
- FCTXAV Food and Cosmetics Toxicology. (London, UK) V.1-19, 1963-81. For publisher information, see FCTOD7. Volume(issue)/page/year: 10,839,1972
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1250 mg/kg
- SEX/DURATION :
- female 11 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
- REFERENCE :
- TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 14,43,1976
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1250 mg/kg
- SEX/DURATION :
- female 11 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - homeostasis
- REFERENCE :
- TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 14,43,1976
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 2500 mg/kg
- SEX/DURATION :
- female 7 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - Central Nervous System
- REFERENCE :
- TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 14,43,1976
Safety Information
| Symbol | GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H360 |
| Precautionary Statements | P201-P308 + P313 |
| Personal Protective Equipment | Eyeshields;Gloves;type P2 (EN 143) respirator cartridges |
| Hazard Codes | Xn:Harmful; |
| Risk Phrases | R22 |
| Safety Phrases | S53-S45 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | UG0700000 |
| HS Code | 2926909090 |
Customs
| HS Code | 2926909090 |
|---|---|
| Summary | HS:2926909090 other nitrile-function compounds VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |
Articles28
More Articles| The Nox1/4 Dual Inhibitor GKT137831 or Nox4 Knockdown Inhibits Angiotensin-II-Induced Adult Mouse Cardiac Fibroblast Proliferation and Migration. AT1 Physically Associates With Nox4. J. Cell Physiol. 231 , 1130-41, (2016) Both oxidative stress and inflammation contribute to chronic hypertension-induced myocardial fibrosis and adverse cardiac remodeling. Here we investigated whether angiotensin (Ang)-II-induced fibrobla... | |
| Inhibitory effects of prostaglandin E2 on collagen synthesis and cell proliferation in human stellate cells from pancreatic head adenocarcinoma. BMC Cancer 14 , 413, (2014) Several studies have described an increased cyclooxygenase-2 (COX-2) expression in pancreatic cancer, but the role of COX-2 in tumour development and progression is not clear. The aim of the present s... | |
| Structural and functional changes in lung tissue of mice fed with beta-aminopropionitrile fumarate, L-3-cis-hydroxyproline, and L-4-cis-hydroxyproline. Respiration 54(2) , 132-8, (1988) Structural and functional changes in lung tissue of mice fed with beta-aminopropionitrile fumarate, L-3-cis-hydroxyproline, and L-4-cis-hydroxyproline. We fed 0.1% solutions of 3-cis-hydroxyproline (3... |
Synonyms
| Propionitrile, 3-amino-, fumarate (2:1) |
| 2-Cyanoethanaminium hydrogen (2E)-but-2-enedioate (1:1:1) |
| 2-aminopropionitril fumarate |
| 3-Aminopropanenitrile (2E)-but-2-enedioate (1:1) |
| Propanenitrile, 3-amino-, (2E)-2-butenedioate (1:1) |
| NH2CH2CH2CN0.5(HO2CCH=CHCO2H) |
| EINECS 218-208-7 |
| bis(3-aminopropiononitrile) fumarate |
| 3-Aminopropionitrile, fumarate |
| Propionitrile, 3-amino-, fumarate |
| B-aminopropionitrile |
| 3-Aminopionitrile Fumarate |
| Propionitrile, 3-amino-, fumarate (1:1) |
| 3-Aminopropionitrile fumarate salt |
| di(2-cyanoethylammonium) fumarate |
| β-Aminopropionitrile, fumarate |
| 2-Cyanoethylamine hemifumarate |
| MFCD00078321 |
| Propanenitrile, 3-amino-, (E)-2-butenedioate (1:1) |
| 3-Aminopropionitrile fumarate |
| B-aminopropionitrile fumarate |
| B-aminopropionitrile monofumarate |
| 3-amino-propionitrilfumarate(2:1) |
| 3-Aminopropanenitrile (2E)-2-butenedioate (1:1) |
| ethanaminium, 2-cyano- (2E)-2-butenedioate, hydrogen salt (1:1:1) |
| EINECS 206-527-4 |
| 3-Aminopropionitrile fumarate (2:1) |
